{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:05:55Z","timestamp":1791187555705,"version":"4.1.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.parkreldis.2011.03.003","type":"journal-article","created":{"date-parts":[[2011,4,15]],"date-time":"2011-04-15T09:43:05Z","timestamp":1302860585000},"page":"379-381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson\u2019s disease"],"prefix":"10.1016","volume":"17","author":[{"given":"C.W.","family":"Hicks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Itin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.H.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.parkreldis.2011.03.003_bib1","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1212\/01.wnl.0000218206.20920.4d","article-title":"Prospective prevalence of pathologic gambling and medication association in Parkinson disease","volume":"66","author":"Voon","year":"2006","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.parkreldis.2011.03.003_bib2","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/archneur.63.7.969","article-title":"Association of dopamine agonist use with impulse control disorders in Parkinson disease","volume":"63","author":"Weintraub","year":"2006","journal-title":"Arch Neurol"},{"issue":"6","key":"10.1016\/j.parkreldis.2011.03.003_bib3","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2165\/00002018-200932060-00004","article-title":"Behavioural adverse effects of dopaminergic treatments in Parkinson\u2019s disease. Incidence, neurobiological basis, management and prevention","volume":"32","author":"Antonini","year":"2009","journal-title":"Drug Saf"},{"issue":"1","key":"10.1016\/j.parkreldis.2011.03.003_bib4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/10401230490281366","article-title":"Impulse control disorders. Clinical characteristics and pharmacological management","volume":"16","author":"Grant","year":"2004","journal-title":"Ann Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.parkreldis.2011.03.003_bib5","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.pbb.2007.12.025","article-title":"A\u00a0double-blind, placebo-controlled trial of olanzapine for the treatment of video poker pathological gamblers","volume":"89","author":"Fong","year":"2008","journal-title":"Pharmacol Biochem Behav"},{"issue":"7","key":"10.1016\/j.parkreldis.2011.03.003_bib6","doi-asserted-by":"crossref","first-page":"559","DOI":"10.4088\/JCP.v63n0704","article-title":"Lithium and valproate treatment of pathological gambling: a randomized single-blind study","volume":"63","author":"Pallanti","year":"2002","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.parkreldis.2011.03.003_bib7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0197-0186(00)00013-9","article-title":"Mechanisms of action of valproate: a commentary","volume":"37","author":"Johannessen","year":"2000","journal-title":"Neurochem Int"},{"issue":"1","key":"10.1016\/j.parkreldis.2011.03.003_bib8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0197-0186(94)90130-9","article-title":"Sodium valproate induced alterations in monoamine levels in different regions of the rat brain","volume":"24","author":"Baf","year":"1994","journal-title":"Neurochem Int"},{"issue":"Suppl. 3","key":"10.1016\/j.parkreldis.2011.03.003_bib9","first-page":"S21","article-title":"Mood stabilization and the role of antipsychotics","volume":"17","author":"Yatham","year":"2002","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.parkreldis.2011.03.003_bib10","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1212\/WNL.47.3.626","article-title":"Reversible parkinsonism and cognitive impairment with chronic valproate use","volume":"47","author":"Armon","year":"1996","journal-title":"Neurology"}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802011000629?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802011000629?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:13:03Z","timestamp":1761178383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802011000629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S1353802011000629"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2011.03.003","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2011.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}